Verona Pharma’s inhaled COPD therapy to be priced at $2,950 per month
June 27 (Reuters) – Verona Pharma’s therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
The U.S. health regulator’s assent on Wednesday for the therapy, branded as Ohtuvayre, provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary disease.
COPD, which causes restricted airflow and breathing problems, affects nearly 16 million Americans and is the sixth leading cause of death in the country, according to government data.
Institute for Clinical and Economic Review, an influential non-profit that evaluates clinical trials and drug prices, in its report dated May-end said the therapy would meet commonly used cost-effectiveness thresholds at an annual price between $7,500 and $12,700.
Ohtuvayre is approved as an add-on maintenance treatment with current COPD therapies and can also be prescribed as a monotherapy.
Verona plans to have around 100 sales representatives reach out to about 15,000 physicians, and expects the therapy to be available in the third quarter.
Source: Reuters
